TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24448936
Drug: Single-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose albendazole (400 mg)
Study: 23289920
Drug: Nitazoxanide-albendazole combination
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide-albendazole combination (1,000 mg-400 mg)
Study: 19822704
Drug: Urtoxazumab (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urtoxazumab (0.1 to 3.0 mg/kg in healthy adults; 1.0 and 3.0 mg/kg in pediatric patients)
Study: 7955800
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate (1.5 mg/kg as 10-minute intravenous infusions every 6 hours for 21 doses)
Study: 3118401
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, 750 mg)
Study: 10803924
Drug: TOR20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR20 (20 mg daily)
Study: 10803924
Drug: TOR40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR40 (40 mg daily)
Study: 14692654
Drug: TOR60 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR60 (60 mg daily)
Study: 8615961
Drug: Chemotherapy, Surgery,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, Surgery, and Radiotherapy (C/S/XRT)
Study: 8615961
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and Radiotherapy (C/XRT)
Study: 25011946
Drug: Exenatide (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10-20 µg/day)
Study: 25011946
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (thrice-daily, titrated to premeal glucose of 5.6-6.0 mmol/L)
Study: 20424250
Drug: B-vitamin therapy
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin therapy (folic acid 2.5 mg/d, vitamin B(6) 25 mg/d, vitamin B(12) 1 mg/d)
Study: 20424250
Drug: B-vitamin therapy
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin therapy
Study: 17414234
Drug: Olanzapine (14.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (14.2 mg/day)
Study: 17414234
Drug: Haloperidol (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (8.5 mg/day)
Study: 12920661
Drug: Insulatard insulin
Normalized name: insulin isophane, human Injectable Suspension [Human Insulatard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulatard insulin
Study: 8812025
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (40 children)
Study: 30267620
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg/week for 12 weeks)
Study: 21875635
Drug: AS03B-adjuvanted split
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03B-adjuvanted split virion H1N1 vaccine
Study: 14748815
Drug: Cocktail of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail of all probe drugs
Study: 11109306
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mHD, nontreated by CC).
Study: 1309691
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (36 mg daily subcutaneous injection)
Study: 6329405
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg oral tablets
Study: 6329405
Drug: Clotrimazole 100
Normalized name: clotrimazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole 100 mg vaginal tablets and 1% cream
Study: 7572582
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 mg
Study: 23901061
Drug: m-CIMT +
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CIMT + IT (intensive therapy)
Study: 20635633
Drug: Low-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose beta-carotene supplementation (1.2 mg daily for six months) + Antihelminthic therapy (400 mg albendazole, two doses)
Study: 20635633
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for beta-carotene + Placebo for antihelminthic therapy
Study: 10322755
Drug: Local produced
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local produced plasma-derived hepatitis B vaccine
Study: 7707121
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clodronate
Study: 2757911
Drug: Vigabatrin (GVG)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (GVG) 1-3 g day-1 for 7 weeks
Study: 2757911
Drug: Long-term GVG
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term GVG therapy (2-4 g day-1) for a mean follow-up of 24 months
Study: 31326681
Drug: Complete revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete revascularization (staged PCI of all suitable non-culprit lesions plus optimal medical therapy)
Study: 10694834
Drug: Cortisol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol 80 mg/day for 5 days
Study: 8222032
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.75 mg.kg‐1 30 min before separation from parents
Study: 3776445
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (4 mg) started peroperatively
Study: 3776445
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (4 mg) started postoperatively
Study: 30224199
Drug: TIV (full-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV (full-dose trivalent inactivated influenza vaccine)
Study: 17582403
Drug: Tailfirst sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailfirst sperm injection
Study: 10197663
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neither medication)
Study: 2181103
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline and doxapram
Study: 29174079
Drug: Surfactant administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administered through a laryngeal mask airway (LMA)
Study: 22659190
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 30 mg/m² and carboplatin AUC 5 plus bevacizumab 10 mg/kg
Study: 24721447
Drug: Microbicide gel
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbicide gel use
Study: 7051564
Drug: Indomethacin, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 75 mg daily for 8.5 months (6-13 months)
Study: 22381065
Drug: Self-help manual
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help manual in addition to standard care and treatment
Study: 22339984
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care and treatment
Study: 19576338
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers at both admission and discharge
Study: 19576338
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers at admission only
Study: 19576338
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers at discharge only
Study: 19576338
Drug: No beta
Normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta blockers at either point
Study: 19576338
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers prescribed at discharge
Study: 19576338
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of valsartan, captopril, and beta blockers
Study: 15235821
Drug: Cremophor EL
Normalized name: cremophor el (polyethoxlated castor oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor EL (CrEL) 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel)
Study: 10841226
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ET results and TnT levels
Study: 9398965
Drug: 1 mg‐kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg‐kg‐1 lidocaine
Study: 9398965
Drug: 0.1 microgram‐1.kg‐1.min‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 microgram‐1.kg‐1.min‐1 PGE1 plus injection of 1 mg‐1.kg‐1 lidocaine
Study: 23206319
Drug: AZD6765 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6765 (150 mg)
Study: 21481253
Drug: MOVE! treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOVE! treatment plus PDA (PDA+)
Study: 21481253
Drug: MOVE! treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOVE! treatment alone (Standard Care)
Study: 19835582
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of GILP
Study: 19835582
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of GILP
Study: 9570600
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg epidural bupivacaine diluted in 4 mL (0.5%)
Study: 9570600
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg epidural bupivacaine diluted in 10 mL (0.2%)
Study: 9570600
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg epidural bupivacaine diluted in 20 mL (0.1%)
Study: 21496343
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention consisting of three targeted pictorial messages regarding vaccines; administered by trained community health workers.
Study: 16615955
Drug: Late provision
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late provision of parenteral amino acids (AA) (n = 836)
Study: 16615955
Drug: Early provision
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early provision of parenteral amino acids (AA) (n = 182)
Study: 11093966
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg daily for 12 weeks
Study: 26791025
Drug: Buccal and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal and lingual infiltrations with 4% articaine and 1:100,000 adrenaline
Study: 24030557
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 1.0 g of Colgate Regular Flavor followed by applying 0.25 g of Tooth Mousse Plus (Group A)
Study: 24030557
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 1.0 g of Colgate Regular Flavor (Group C)
Study: 20681273
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule (XZK) at a dose of 60 mg, twice a day, combined with hypotensive drugs
Study: 20681273
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hypotensive drugs only)
Study: 20681273
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule (XZK) combined with hypotensive drugs
Study: 16298239
Drug: Insulin (induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (induced hyperinsulinemia)
Study: 14616791
Drug: ALM mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALM mixed with low dose of BCG
Study: 10810001
Drug: Lipase inhibitor
Normalized name: Lipase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipase inhibitor
Study: 26755098
Drug: Ragweed SLIT
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed SLIT tablet (12 Ambrosia artemisiifolia 1-U) and grass SLIT tablet
Study: 26507709
Drug: Timothy grass
Normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy grass SLIT tablet
Study: 26755098
Drug: Ragweed SLIT
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed SLIT tablet and grass SLIT tablet
Study: 21095309
Drug: Glue or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glue or patch or buttressing
Study: 12865592
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (2 mg/day) + norethisterone acetate (1 mg/day)
Study: 12865592
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.05 mg) + norethisterone acetate (0.25 mg)
Study: 19193505
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg/day)
Study: 29027510
Drug: Topical hydroquinone
Normalized name: hydroquinone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydroquinone (HQ) 2% applied once nightly for three months
Study: 27209504
Drug: Sequential chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiation therapy
Study: 11530042
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment sequences
Study: 25684611
Drug: Game+Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Game+Therapy
Study: 16570004
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal group
Study: 10102962
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy group
Study: 7903214
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg plus diuretic
Study: 3960619
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 12.5 mg/L of zinc
Study: 21105483
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine (0.35 mg/kg)
Study: 21105483
Drug: Group E
Normalized name: Prostaglandin group E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E (Intravenous)
Study: 18681202
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy and radiotherapy
Study: 15938592
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (250 microg subcutaneous) with a slow, four-stage, 4-week titration
Study: 1574915
Drug: Combined immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunization with purified Vero cell rabies vaccine and Typhim Vi
Study: 1574915
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero cell rabies vaccine
Study: 6397973
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amphetamine sulfate
Study: 6397973
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg amphetamine sulfate
Study: 6397973
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ephedrine hydrochloride
Study: 6397973
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ephedrine hydrochloride
Study: 6397973
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (combined results of amphetamines and ephedrine)
Study: 2671282
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone
Study: 17134627
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion (30% glucose, 50 IU of insulin, 80 mEq of potassium chloride infused at 1.5 ml/kg/hour over 24 hours)
Study: 10971306
Drug: S-heparin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-heparin (50 IU kg(‐1) via i.v.)
Study: 10971306
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline via i.v. injection)
Study: 1451221
Drug: Nicardipine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine infusion (0.5‐2.0 micrograms.kg‐1 x min‐1)
Study: 1451221
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion (0.05‐0.2 microgram.kg‐1 x min‐1)
Study: 19545976
Drug: Olanzapine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (7.5 mg)
Study: 22311903
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of yohimbine (5.4 mg) and atomoxetine (18.0 mg)
Study: 6103707
Drug: Flunitrazepam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.5 mg oral
Study: 6103707
Drug: Flunitrazepam 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1.0 mg oral
Study: 6103707
Drug: Flunitrazepam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2.0 mg oral
Study: 6103707
Drug: Flunitrazepam i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam i.m. administration
Study: 8081180
Drug: Flunitrazepam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (all doses)
Study: 23375074
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg potassium iodide (KI)/d
Study: 23375074
Drug: 300 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 μg potassium iodide (KI)/d
Study: 20549511
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 40 mg
Study: 20549511
Drug: Misoprostol 40
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 40 mg vaginally
Study: 16986383
Drug: Heparin (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (unfractionated or low-molecular-weight)
Study: 25184864
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IIV3)
Study: 8665548
Drug: Selegiline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (5 mg b.i.d.)
Study: 2014933
Drug: Volmax, 8
Normalized name: Volmax, 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volmax, 8 mg bid
Study: 2014933
Drug: Proventil Repetabs,
Normalized name: Proventil Repetabs, 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proventil Repetabs, 8 mg (as two 4-mg tablets) bid
Study: 29203772
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral challenge
Study: 19762295
Drug: Other analgesic
Normalized name: OTHER ANALGESICS AND ANTIPYRETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other analgesic procedures
Study: 15347340
Drug: Bepotastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine (10 mg twice a day)
Study: 15347340
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg once a day)
Study: 15347340
Drug: Fexofenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (60 mg twice a day)
Study: 24303975
Drug: Olopatadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine (5 mg twice a day)
Study: 9868589
Drug: Antioxidants from
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants from food; specific dosage and duration not available.
Study: 9868589
Drug: Antioxidant therapy;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy; specific details not available.
Study: 7993987
Drug: Two 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 10 mg controlled-release nifedipine tablets (Adalat Retard, Bayer), administered 12 hourly
Study: 7993987
Drug: One 20
Normalized name: DIMETHICONE 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 20 mg controlled-release nifedipine tablet (Adalat Retard, Bayer), administered 12 hourly
Study: 7993987
Drug: Two 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 30 mg nifedipine gastro-intestinal therapeutic system (GITS) tablets (Adalat XL, Bayer), administered once daily
Study: 7993987
Drug: One 60
Normalized name: apazone 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 60 mg nifedipine GITS tablet (Adalat XL, Bayer), administered once daily
Study: 7993987
Drug: One 20
Normalized name: DIMETHICONE 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 20 mg plus one 10 mg nifedipine controlled-release tablet (Adalat Retard, Bayer), administered 12 hourly
Study: 18834731
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 10 mg (n = 65)
Study: 10812581
Drug: ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofibrate 100 mg
Study: 1290434
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg maintenance dose
Study: 21922202
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg betamethasone i.v. prior to vinorelbine infusion
Study: 21922202
Drug: Placebo i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. prior to vinorelbine infusion
Study: 21922202
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml saline infusion post vinorelbine infusion